ImpediMed Stock

ImpediMed Debt

The Debt of ImpediMed (IPD.AX) as of Aug 11, 2026 is -7.69 M AUD. In the previous year, Debt was -23.49 M AUD — a change of -67.25% (higher).

Debt

-7.69 MAUD

YoY

-67.25%

Last updated:

In 2026, ImpediMed's total debt was -7.69 M AUD, a -67.25% change from the -23.49 M AUD total debt recorded in the previous year.

Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Debt Details

Understanding ImpediMed's Debt Structure

ImpediMed's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing ImpediMed's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to ImpediMed’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in ImpediMed’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about ImpediMed stock

Debt of ImpediMed is -7.69 M AUD in 2026.

Debt of ImpediMed changed from -23.49 M AUD to -7.69 M AUD, representing a -67.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's ImpediMed historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ImpediMed

All Key Metrics — ImpediMed